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Inﬂammatory markersAbstract Background: COPD is a chronic disease of the lungs characterized by increased obstruc-
tion to airﬂow that does not change markedly over periods of several months. Low-grade systemic
inﬂammation is considered a hallmark of COPD that potentially links COPD to increased rate of
systemic manifestations of the disease. Evaluation of systemic inﬂammation in COPD particularly
when the disease is severe and during exacerbation can be measured either as increased circulating
cytokines, chemokines and acute phase proteins, or as abnormalities in the circulating cells and
markers. One of these inﬂammatory mediators is IL-1B which demonstrated recent reports in sig-
niﬁcantly high levels of IL-1b in serum of the COPD patients as compared to the healthy controls.
Aim of the study: To assess the level of serum IL-1B in chronic obstructive pulmonary disease
patients during acute exacerbation and in stable conditions and also, to determine if the changes
in its level correlated with changes in the ventilatory functions.
Methods: 80 cases were included in this study: 60 COPD patients and 20 healthy subjects as a
control. There were 48 males and 12 females in COPD groups and 17 males and 3 females in the
control group. Their age ranged from 41 to 79 years with a mean age of 59 years. The subjects were
classiﬁed into 3 groups. Group I includes (30) patients with acute exacerbation of COPD. Group II
includes (30) patients with stable controlled COPD. Group III includes (20) healthy persons as a
control.
Results: There was a highly statistically signiﬁcant difference in serum IL-1B (pg/ml) between
studied groups, which indicates that IL-1B plays a role in systemic inﬂammatory process. There
was a highly statistically signiﬁcant difference in serum IL-1B concentration (pg/ml) and severity
of COPD cases.
Conclusions: IL-1b correlated with clinical aspects of disease severity, suggesting that IL-1b may
play a critical role in COPD.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).rculosis.
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Chronic obstructive pulmonary disease (COPD), a common pre-
ventable and treatable disease, is characterized by airﬂow limita-
tion that is usually progressive and associated with an enhanced
chronic inﬂammatory response in the airways and the lung to nox-
ious particles or gases. Exacerbations and comorbidities contribute
to the overall severity in individual patients [7]. An exacerbation of
COPD is deﬁned as an acute event characterized by worsening of
the patient’s respiratory symptoms that is beyond normal day to
day variations and leads to a change in medication. [7].
COPD is associated with a chronic inﬂammatory response,
predominantly in small airways and lung parenchyma, which is
characterized by increased numbers of macrophages, neutro-
phils, and T lymphocytes. The inﬂammatory mediators
involved in COPD have not been clearly deﬁned, in contrast
to asthma, but it is now apparent that many lipid mediators,
inﬂammatory peptides, reactive oxygen and nitrogen species,
chemokines, cytokines, and growth factors are involved in
orchestrating the complex inﬂammatory process that results
in small airway ﬁbrosis and alveolar destruction. Many prote-
ases are also involved in the inﬂammatory process and are
responsible for the destruction of elastin ﬁbers in the lung
parenchyma, which is the hallmark of emphysema. The identi-
ﬁcation of inﬂammatory mediators and understanding their
interactions are important for the development of anti-inﬂam-
matory treatments for this important disease [3]. Interleukin-
1beta (IL-1beta) is a proinﬂammatory cytokine. It is a potent
activator of alveolar macrophages from COPD patients [14].
In COPD IL-1beta serum level correlates with clinical
aspects of disease severity [17].
Subjects and methods
This study was created on 80 subjects, 60 COPD patients admitted
in Tanta Chest Hospital in the period between August 2013 and
April 2014 plus 20 apparently healthy control subjects, selected
from volunteers and patients relatives. There were 48 males and
12 females in COPD groups and 17 males and 3 females in the
control group. Their age ranged from 41 to 79 years with a mean
age of 59 years. The subjects were classiﬁed into 3 groups:
Group I: includes (30) patients with acute exacerbation of
COPD.
Group II: includes (30) patients with stable controlled
COPD.
Group III: includes (20) healthy persons as a control.
The patients will be diagnosed based on the severity of
COPD according to [7] using spirometry as follows:
GOLD 1: Mild FEV1P 80% predicted
GOLD 2: Moderate 50% 6 FEV1 < 80% predicted
GOLD 3: Severe 30% 6 FEV1 < 50% predicted
GOLD 4: Very severe FEV1 < 30% predictedInclusion criteria
Patients with COPD diagnosed according to GOLD [7]
criteria.Exclusion criteria
(Due to possible effects on lung function):
Patients with pneumonectomy, lung cancers.
Patients with residual extensive tuberculous lesion or active
disease.
Patients with diabetes mellitus, collagen vascular disorders.
Patients with renal and hepatic disorders and those on sys-
temic anti inﬂammatory therapy.
A written consent will be taken from all patients.
All subjects were submitted to the following:
1. History taking with the stress on:
History of smoking (types and smoking index).
History of chest symptoms (cough, expectoration, dysp-
nea and wheeze).
History of any other co-morbidities as diabetes mellitus,
tuberculosis, hepatic disease, renal disease, collagen vas-
cular diseases.
2. Clinical examination both general and local.
3. Body mass index (BMI) was calculated as the weight in kg
divided by height2.
4. Complete blood count, liver function tests, kidney function
tests.
5. Radiological examination: Plain X-ray chest P-A view.
6. Pulmonary function tests (spirometry) before and after
broncho dilatation.
7. Serum levels of interleukin- 1 beta (IL- 1B):
Results
The results are presented in Tables 1–12.
Discussion
Table 1 shows that the mean age of COPD patients in group I
was 57.5 ± 9.81 years. The mean age of COPD patients in
group II was 61.4 ± 6.78 years. And the mean age of COPD
patients in group III was 55.05 ± 9.25 years. There was a
non-signiﬁcant difference between COPD patients in group I,
group II and group III as regards age.
Tables 2 and 3 show comparison between pulmonary func-
tions before and after using bronchodilator in COPD groups.
In this study pre and post bronchodilator spirometry was
done among 60 patients known to have COPD and showed
partial reversibility in the FEV1% pred. (less than 12%) con-
ﬁrming the diagnosis of COPD cases (Tables 3 and 4).
The decline in forced expiratory volume in 1st second
(FEV1%) in COPD is mainly related to thickening of the walls
of small conducting airways and obstruction of these airways
by mucous exudates [8]. This could be explained by the effect
of smoking which induces structural changes in small and large
airways, and is considered a major factor in the development
of airﬂow obstruction in chronic obstructive pulmonary dis-
ease [4]. In the current study pre and post bronchodilator spi-
rometry was done for group I and II, there were signiﬁcant
differences in spirometric data between the two groups
(p< 0.01).
Table 1 Demographic data and statistical analysis of the
studied groups as regards age.
Age/year Group
Group I Group II Group III Sig.
Range 41–79 48–73 38–62
Mean ± SD 57.5 ± 9.81 61.4 ± 6.78 55.05 ± 9.25
F test 3.566 NS
p Value 0.127 NS
Scheﬀe test
*P1 value 0.156 NS
*P2 value 0.203 NS
*P3 value 0.092 NS
*P1: comparison between group I and group II.*P2: comparison
between group I and group III.*P3: comparison between group II
and group III.
This table shows a non-signiﬁcant difference in age between the
studied groups.
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ence in the smoking index between the two groups of COPD
patients (Table 4).
This result is in agreement with [13], who found that several
studies show a signiﬁcant excess decline in FEV1 in smokers
over non-smokers, ex-smokers and quitters.
This result is also in agreement with [12] who found that in
smokers, the risk of developing COPD is dose related.
In the current work it was found that there is a signiﬁcant
correlation between smoking index and IL-1B in group I and
II (Tables 8 and 9).Table 2 Comparison between pre-bronchodilator spirometry in CO
Group
Group I
FVC% pred Pre 51 ± 10.6
FVC L/m Pre 2.24 ± 0.54
FEV1% pred Pre 40.4 ± 12.1
FEV1 L/m Pre 1.18 ± 0.32
FEV1/FVC% pred Pre 50.4 ± 8.3
FEF 25–75% pred Pre 23.6 ± 5.7
FEF 25–75% L/M Pre 0.76 ± 0.46
This table shows a signiﬁcant difference in pre-bronchodilator FVC% pre
group I and II.
Table 3 Comparison between post-bronchodilator spirometry in C
Group
Group I
FVC% pred Post 62.7 ± 11.2
FVC L/m Post 2.29 ± 0.58
FEV1 pred Post 41.8 ± 12.5
FEV1 L/m Post 1.27 ± 0.34
FEV1/FVC% pred Post 51.7 ± 9.1
FEF 25–75% pred Post 26.1 ± 12.2
FEF 25–75% L/M Post 0.81 ± 0.45
This table shows a non-signiﬁcant difference in post-bronchodilator FVC%
in post-bronchodilator FEV1% pred, FEV1/FVC% pred and FEF 25–7This result is in agreement with [13], who reported that
smoking results in a non-speciﬁc increase in IgE as a result
of interference with IgE regulatory mechanisms and IL-1B
expression may be induced in monocytes due to increased
IgE levels, which may lead to their increased release in blood.
This also matched with [10] who found that subjects with
lower FEV1 may have higher exposure to tobacco smoke or
to environmental insults that lead to a subtle decline in lung
function and, in parallel, induce a low-grade inﬂammatory
response.
Based on the results of post bronchodilator spirometry 9
patients were classiﬁed as stage II (FEV1:50–80% predicted),
16 patients as stage III (FEV1:30–50% predicted) and 5
patients were classiﬁed as stage IV (FEV1: less than30% pre-
dicted) according to GOLD [7] in group I. And according to
this study in Table 5 it was found that 6 patients who were
admitted to ICU represent 20% of patients in group I.
This result agreed with [5], who found that there is a range
of severity among patients hospitalized with AECOPD, with
the more severely ill patients needing either non-invasive posi-
tive pressure ventilation (NIPPV) or endotracheal intubation
and ventilation. As one would expect, patients admitted to
the intensive care unit (ICU) have worse outcomes and
increased mortality, but the use of NIPPV may provide some
beneﬁt. One study showed that ICU patients initially placed
on mechanical ventilation had a much higher mortality
[adjusted odds ratio (OR) 15.7; 95% conﬁdence interval
(CI)4.2,59] than patients placed on NIPPV.
In this present work it was observed that the mean range of
duration of admission among COPD patients was 13.1 ± 6.3PD groups.
t Test p Value Sig.
Group II
55.4 ± 9.9 3.52 0.021 S
2.45 ± 0.54 2.96 0.036 S
42.3 ± 6.9 5.326 0.005 S
1.17 ± 0.24 4.489 0.020 S
54.1 ± 7.1 2.13 0.017 S
24.9 ± 7.16 2.35 0.024 S
0.67 ± 0.32 4.518 0.005 S
d, FEV1 % pred, FEV1/FVC% pred and FEF 25–75% pred between
OPD groups.
t Test p Value Sig.
Group II
63.8 ± 9.46 1.53 0.236 NS
2.30 ± 0.52 0.147 0.520 NS
44.7 ± 5.79 4.935 0.007 S
1.29 ± 0.22 2.142 0.048 S
54.7 ± 8.7 3.201 0.039 S
25.1 ± 7.52 4.130 0.020 S
0.66 ± 0.38 3.201 0.027 S
pred between group I and II. While there was a signiﬁcant difference
5% pred between group I and II.
Table 4 Comparison between COPD groups as regards the smoking index.
Smoking index Group I Group II Total X2 P value
No. % No. % No. %
Mild 0 0 2 7.7 2 4 4.629 0.030* S
Moderate 6 25 8 30.8 14 28
Sever 8 33.3 9 34.6 17 34
Very severe 10 41 7 26.9 17 34
Total 24 100 26 100 50 100
This table shows a signiﬁcant difference between the two groups of COPD patients and the smoking index, while group III was non-smoker.
Table 5 Percentage of ICU admission among Group I COPD
patients.
ICU admission
N %
Yes 6 20
No 24 80
Total 30 100
This table shows 20% of patients were admitted in ICU, while 80%
of patients not admitted.
Table 6 Duration of admission among COPD patients.
Minimum Maximum Mean ± SD
Duration of admission (days) 5 30 13.1 ± 6.3
This table shows the mean range of duration of admission among
COPD patients 13.1 ± 6.3 with Maximum period 30 days and
Minimum period 5 days.
Table 7 Levels of serum IL-1B (pg/ml) among the studied
groups.
IL-1B (pg/ml) Group Sig.
Group I Group II Group III
Range 3.6–6.8 2.4–4 1.2–3
Mean ± SD 5.15 ± 0.80 3.29 ± 0.43 1.52 ± 0.15
F test 11.639
p Value 0.001* HS
Scheﬀe Test
*P1 value 0.006* HS
*P2 value 0.001* HS
*P3 value 0.001* HS
*P1: comparison between group I and group II.*P2: comparison
between group I and group III.*P3: comparison between group II
and group III.
This table shows a highly signiﬁcant difference in levels of serum
IL-1B (pg/ml) among the studied groups.
Table 8 Correlation between serum IL-1B (pg/ml) and the
smoking index of acute exacerbation (group I) of COPD cases.
Group I IL-1B (pg/ml)
r P value Sig
Smoking index 0.425 0.017 S
This table shows a positive signiﬁcant correlation between serum
IL-1B (pg/ml) and smoking index of group I.
Table 9 Correlation between serum IL-1B (pg/ml) and the
smoking index of controlled COPD cases (group II).
Group II IL-1B (pg/ml)
r P value Sig
Smoking index 0.325 0.032 S
This table shows a positive signiﬁcant correlation between serum
IL-1B (pg/ml) and smoking index of group II.
Table 10 Correlation between serum IL-1B (pg/ml) and ICU
admission and duration of admission of group I.
Group I IL-1B (pg/ml)
r P value Sig
ICU admission 0.285 0.027 S
Duration of admission (days) 0.714 0.253 NS
This table shows a signiﬁcant correlation between serum IL-1B (pg/
ml) and ICU admission of group I, while there was a non-signiﬁ-
cant correlation in duration of admission between serum IL-1B (pg/
ml) and the same group I.
Table 11 Correlation between serum levels of IL-1B and
severity of COPD according to [7] in group I.
IL-1B (pg/ml) GI
Moderate Severe V. severe
Range 3.6–5.8 4.18–6.8 5.7–6.1
Mean ± SD 4.30 ± 0.69 5.20 ± 0.64 5.90 ± 0.15
F test 5.325
p Value 0.001
Sig HS
This table shows a highly signiﬁcant correlation between IL-1B and
severity of COPD in group I.
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which represent a wide range (Table 6).
This is in agreement with [6] who found that lower FEV1
was associated with higher rates of COPD exacerbations and
readmissions.
Table 12 Correlation between serum levels of IL-1B and
severity of COPD according to [7] in group II:
IL-1B (pg/ml) GII
Moderate Severe V. severe
Range 2.4–3.2 2.7–3.9 3.5–4
Mean ± SD 2.87 ± 0.28 3.33 ± 0.36 3.82 ± 0.22
F test 6.325
p Value 0.008
Sig HS
This table shows a highly signiﬁcant correlation between IL-1B and
severity of COPD in group II.
Serum interleukin-1 beta as an inﬂammatory marker in COPD patients 351In this current study it was reported that there is a highly
signiﬁcant difference in the level of IL-1B between the three
groups. The level of (IL-1Beta) was related to the stage of
the disease as there was a signiﬁcant increase in (IL-1Beta)
level with increasing severity of COPD; very severe COPD
cases have a higher level of (IL-1Beta) than severe and moder-
ate cases, (IL-1Beta) was also raised in severe cases than mod-
erate cases and the difference between them was highly
statistically signiﬁcant (p< 0.01) (Table 7).
This is matched with [1], who reported that COPD results
from airway inﬂammation involving multiple inﬂammatory
mediators and tissue damage.
This could be explained by the nature of COPD as a com-
plex chronic inﬂammatory disease of the lungs involving sev-
eral types of inﬂammatory cells and a variety of
inﬂammatory mediators. Although primarily affecting the
lungs, the chronic inﬂammatory process of COPD does have
systemic repercussions [2].
This result is in agreement with [16], who found that there is
a signiﬁcantly high level of IL-1b in serum of the COPD
patients as compared to the healthy controls. A few studies
previously undertaken have also reported a rise in IL-1b in
COPD cases.
Also this result is in agreement with [17], who reported that
in the control group, the IL-1b level was 2.11 ± 0.16 pg/ml
(range: 0.39–2.97 pg/ml), which was signiﬁcantly lower than
COPD patients (3.14 ± 0.07, range: 2.8–4.59 pg/ml, p< 0.05).
Sapey et al. [16], proved that there are increased levels of
circulating cytokines and acute phase reactants have been seen
in the peripheral circulation of patients suffering from COPD,
especially during exacerbations. They also proved that IL-1b
plays a critical role in COPD where it was found to correlate
signiﬁcantly with FEV1 suggesting its role in clinical aspects
of disease severity.
All these results are in agreement with [9], who concluded
that modulation of various inﬂammatory mediators may help
in combating the clinical outcome of COPD and may have
therapeutic implications whereas determination of serum IL-
1b levels may help in differentiating COPD from other respira-
tory disorders such as asthma.
On the contrary, this result disagreed with [15], who proved
that IL-1b may be related to pathophysiology in COPD,
although there were no signiﬁcant differences in IL-1b concen-
trations between their groups (Table 10).
In this current work it was found that there is a highly sig-
niﬁcant correlation between IL-1B and COPD severity in
groups I and II (Table 11 and 12).This result matched with [11], who found that IL-1b expres-
sion in COPD neutrophils correlates with disease severity. This
result is also in agreement with [16], when studying the demon-
stration of IL-1B and TNF levels in serum and sputum, he
found that IL-1B plays a critical role in COPD where it was
found to correlate signiﬁcantly with FEV1 suggesting its role
in clinical aspects of disease severity.
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